Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Cyclacel Still Steeped In Doubt

Around five months ago, I thought Cyclacel Pharmaceuticals (NASDAQ:CYCC) looked like an interesting speculative biotech play, as the market seemed to be hugely pessimistic on a drug (sapacitabine) that had shown encouraging evidence of efficacy in a seriously under-treated patient population. Since that report (and two by Seeking Alpha contributor Scrying Biotech), the shares are up about 50% and I would argue that these shares are still an interesting speculation for the risk-seeking biotech investor.

To be very clear, I'm still not unreservedly bullish on these shares. I think bears will remain fixated on the risks represented by running a Phase III trial with an unapproved drug as a control, not to mention the more typical risk...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details